Rigel Pharmaceuticals (RIGL) Return on Capital Employed (2011 - 2026)

Rigel Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 29.69% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 1282.0% year-over-year to 29.69% in Q1 2026; TTM through Mar 2026 was 29.69%, a 1282.0% decrease from a year earlier, with the FY2025 full-year figure at 52.38%, up 2108.0% from the prior year.
• Return on Capital Employed fell to 29.69% in Q1 2026 per RIGL's latest filing, from 45.0% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 99.87% in Q2 2025 and bottomed at 106.05% in Q3 2022.
• The 5-year median for Return on Capital Employed is 30.0% (2023), against an average of 13.54%.
• Across the five-year window, Return on Capital Employed slumped 9870 bps in 2022 and soared 11298 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 93.0% in 2022, then jumped by 65 bps to 32.52% in 2023, then jumped by 184 bps to 27.37% in 2024, then soared by 64 bps to 45.0% in 2025, then plunged by 34 bps to 29.69% in 2026.
• Per Business Quant, the three latest RIGL Return on Capital Employed figures stand at 29.69% (Q1 2026), 45.0% (Q4 2025), and 91.34% (Q3 2025).